Charles R. Kummeth has served as CEO of Bio-Techne Corporation since April 2013. He has a background in product and brand development, previously holding key positions at Thermo Fisher Scientific and 3M. Under his leadership, Bio-Techne reached impressive financial milestones,...
Charles R. Kummeth has served as CEO of Bio-Techne Corporation since April 2013. He has a background in product and brand development, previously holding key positions at Thermo Fisher Scientific and 3M. Under his leadership, Bio-Techne reached impressive financial milestones, including a net sales increase to $714 million by 2019. Kummeth is preparing to retire in June 2024, transitioning to a Senior Advisor role to ensure a smooth leadership handover. Notably, his 2023 compensation was around $30.5 million, backed heavily by vested stock awards reflecting past performances. A unique part of his legacy is how he structured his compensation during a two-year transition plan designed to encourage long-term growth and stability within the company. Kummeth's tenure highlights the importance of strong executive leadership in navigating growth in the competitive biotechnology market and aligning company performance with shareholder interests. His focus on strategic acquisitions has also diversified Bio-Techne’s product offerings significantly. Kummeth's career encompasses a variety of business strategies that emphasize innovation, operational efficiency, and market expansion, which have solidified his reputation in the biotech industry.